Posts

FDA delays camizestrant breast cancer drug decision after ODAC vote against benefit-risk profile

on

Biopharma Bites: AstraZeneca's Camizestrant Faces FDA ODAC Scrutiny Amid Trial Design Concerns

on

FDA's Oncologic Drugs Advisory Committee to Review AstraZeneca's Cancer Drugs in First Meeting in 9 Months

on

FDA Advisory Committee Votes Against GSK's Blenrep in Multiple Myeloma

on

FDA Advisory Committee Splits Votes on Genentech and J&J Cancer Drugs

on